SynVivo Scientific Publication Featured as Cover Story for Journal of Controlled Release

Journal of Controlled ReleaseHuntsville, AL – February 27, 2015 – CFD Research Corporation is proud that the editors of the Journal of Controlled Release have selected a new paper from Prabhakar Pandian and SynVivo co-authors Charles Garson, Ivy Mills, and Kapil Pant as the cover of this prestigious journal publication. The paper describes the team's work to reproduce a realistic and dynamic tumor microenvironment and its use in screening drug delivery systems. The studies were performed using the SynVivo co-culture microfluidic cell-based assay device whereby they created an in vitro tumor microenvironment encompassing circulatory flow in the vessels, transport across the leaky vasculature near the tumor region and real-time visualization of drug deliver to 3D culture of tumor cells.

Read more: SynVivo Scientific Publication Featured as Cover Story for Journal of Controlled Release

Blood Brain Barrier on a Chip Could Stand in for Children in Paediatric Brain Research

Bethesda, MD (Scicasts) - December 5, 2014 — In the human brain, the BBB is not the Better Business Bureau but the blood brain barrier and the BBB is serious business in human physiology. The human BBB separates circulating blood from the central nervous system, thus protecting the brain from many infections and toxins. But the BBB also blocks the passage of many potentially useful drugs to the brain and it has long stymied scientists who want to learn more about this vital tissue because of the lack of realistic non-human lab models. Even less is known about the BBB in children.

Read more: Blood Brain Barrier on a Chip Could Stand in for Children in Paediatric Brain Research

SynVivo recognized among “Top 10 Innovations of 2013” by The Scientist

HUNTSVILLE, Ala. December 4, 2013 - CFD Research Corporation developed SynVivo® microfluidic cell-based assay platform has been recognized as one of the "Top 10 Innovations of 2013" by The Scientist magazine. SynVivo enables faster, more efficient drug development by combining the control of in vitro testing with the realism of in vivo studies.

Read more: SynVivo recognized among “Top 10 Innovations of 2013” by The Scientist

CFDRC Developing Physiologically Realistic in vitro Tumor Microenvironment Platform

SynVivo-Tumor offers real-time analysis and visualization of drug delivery and cellular interactions and will be showcased at the December ASCB meeting in San Francisco.

HUNTSVILLE, Ala. December 10, 2012 - CFD Research Corporation has been awarded a $1.3M grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors.

Read more: CFDRC Developing Physiologically Realistic in vitro Tumor Microenvironment Platform

Join Our Mailinglist